Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Publisher: La Merie Publishing
Pages: 180
Format: PDF and Online
Product Line:
Competitor Analysis
Product Code: LMCA0120
Release Date: June of 2016

500.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory & Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic, ophthalmic and pulmonary diseases as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Tremendous progress in bispecific antibody technologies during the last decade have lead to an explosion of bispecific antibodies in clinical development. This report describes 47 clinical and further 25 pre-IND stage bispecific antibodies in addition to numerous preclinical R&D endeavours. The two specificities provide flexibility in the use as:

  • T-Cell or NK cell redirecting bispecific cancer antibodies
  • Bispecific immuno-oncology antibodies
  • Bispecific tumor antigens targeted cancer antibodies
  • Bispecific antibodies for inflammatory & autoimmune diseases
  • Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The report includes a compilation of currently active projects in development of bispecific therapeutic antibodies including cocktails of antibodies as well as oligo- and polyclonal antibodies. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Table of Contents

1.         Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

  • T-Cell Redirecting Bispecific Cancer Antibodies
  • NK Cell Redirecting Bispecific Cancer Antibodies
  • Bispecific Immuno-Oncology Antibodies
  • Bispecific Tumor Antigens Targeted Cancer Antibodies
  • Bispecific Antibodies for Inflammatory & Autoimmune Diseases
  • Bispecific Antibodies Outside Oncology & Inflammation
  • Antibody Cocktails & Oligo- and Polyclonal Antibodies

2.         Corporate Bispecific Antibody Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top